Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences:
馬薩諸塞州沃爾塞姆，2024年11月27日（環球新聞通訊社）-- Apellis製藥公司（納斯達克：APLS）今天宣佈公司將參加以下12月份的投資者會議：
- Evercore ISI HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 9:10 a.m. ET
- Citi Global Healthcare Conference: Fireside chat on Thursday, December 5, 2024, at 1:00 p.m. ET
- Evercore ISI HealthCONx Conference: 2024年12月4日(星期三)上午9:10舉行爐邊聊天
- 花旗全球衛生保健會議: 2024年12月5日(星期四)下午1:00舉行爐邊聊天
The live conference webcasts will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcasts will be available for approximately 90 days following the event.
現場會議網絡直播將發佈在公司網站的「投資者與媒體」版塊的「事件和演講」頁面上。回放將在活動結束後大約90天內提供。
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit or follow us on Twitter and LinkedIn.
關於Apellis
Apellis Pharmaceuticals是一家全球生物製藥公司，結合勇敢的科學和同情心，爲一些最具挑戰性的疾病患者開發改變生命的治療方案。我們推出了15年來第一個新的補體藥物系，現有兩種針對C3的批准藥物，其中包括全球首款用於地理萎縮症的治療。我們相信，我們才剛剛開始釋放針對C3治療嚴重眼部、罕見和神經系統疾病的潛力。欲了解更多信息，請訪問或關注我們的Twitter和LinkedIn。
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
投資者聯繫：
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
譯文內容由第三人軟體翻譯。
